Multiple Sclerosis - Better Drugs But No Cure in SightConsiderable activity in anti-inflammatories and vaccines should lead to a $1.3 billion US market in 2010.
Sleepiness, fatigue, and risk of obstructive sleep apnea using the STOP-BANG questionnaire in multiple sclerosis: a pilot study. This study aims: (1) to identify patients with multiple sclerosis (MS) who are at high risk for obstructive sleep apnea (OSA) by utilizing the STOP-BANG qu... ...
Comparable Estimates - Multiple Sclerosis Drugs (Worldwide) in billion USD (US$) Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date. ...
In Australia & Oceania, the Multiple Sclerosis Drugs market is projected to witness a substantial increase in revenue, with a projected amount of US$224.70m in 2024. Looking ahead, the market is expected to maintain a steady growth rate, with a compound annual growth rate (CAGR 2024-2029) ...
Corticotropin, adrenal cortical steroids, alkylating agents, and antimetabolites are being used to treat multiple sclerosis (MS). The benefits of these substances must be carefully weighed against the risks. While the steroids appear to improve neurologic function lost in acute relapses, they do not...
Multiple Sclerosis Drugs Market (Drug Class: Interferon Beta, Sphingosine 1 Phosphate Receptor Modulators, Mixed Polymers, NF-KB Inhibitor, Pyrimidine Synthesis Inhibitor, Monoclonal Antibodies, Corticosteroids, Adrenocorticotropic Hormone, and Others; Disease Type: Relapsing-remitting MS (RRMS), Primary-...
BCC’s goal in conducting this study was to determine the current status of the market for disease-modifying multiple sclerosis (MS) drugs, biologics, and vaccines and to assess their growth potential over a 5-year period from 2010 through 2015. ...
A computing device-implemented method includes receiving a program created by a technical computing environment, analyzing the program, generating multiple program portions based on the analysis of the program, dynamically allocating the... JN Little,JF Hicklin,JL Martin,... - US 被引量: 35发表:...
Are Your MS Drugs Working? Learn More on Is multiple sclerosis hereditary? What is the life expectancy? Genetic factors don't seem to play a large role in the disease. Although people who have a first-degree relative with MS have a slightly higher risk of developing it themselves, this ...
The Multiple Sclerosis Drugs market in Czechia is forecasted to achieve a revenue of US$40.11m in 2025. This market is expected to exhibit a compound annual growth rate (CAGR 2025-2029) of 1.10%, leading to a market volume of US$41.90m by 2029. In terms of global comparison, United Sta...